Discover and share articles, posts, and links from across the web.
Backtesting feels productive. You write a strategy, run it against 5 years of historical data, watch the equity curve trend up and to the right, and start da...
How I Built a Memory-Safe Steganography Engine in Rust to Protect Data from AI Scrapers As AI models scale, data provenance is becoming a massive engineering...
I've been working with OpenClaw for managing AI agents, and I kept running into the same problems: juggling multiple instances for different environments, ma...
Your sales rep is halfway through a demo when the prospect asks: "Can your product do X? We heard [a competitor] just added that last month." You had no idea...
The problem Everyone has opinions about what engineers should do in response to AI. Almost no one has data about what they actually do. I wanted data. What I...
What is Docling ??? Docling is an open source document processing library that converts various document formats into structured outputs. Docling plays an im...
The EV giant will likely release actual Q1 delivery figures on April 2.
Flash flooding threatens the wheatbelt region and Perth, as weather system expected to continue south-east from Geraldton on SaturdayGet our breaking news em...
The company crushed bottom-line estimates in its final quarter of 2025.
This error could really trip you up.
This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.
This investment offers a terrific combination of likely price appreciation along with dividend income.
It was a historic stretch of time for the biotech.
As stocks sell off, here's one of the Magnificent Seven stocks I think has fallen enough to make it a buy.
This spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.
Analysts think Nebius, Microsoft, and Nvidia have huge upsides.
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.
LeMaitre Vascular, a specialist in vascular medical devices, reported a notable insider sale amid strong recent share gains.
Data centers devour energy. Argan builds the power plants that feed them.
If the defense budget tops $1 trillion, Lockheed stands to make a fortune.
This annuities and life insurance provider saw a notable insider buy amid a year marked by sharp share price declines and sector headwinds.
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
These two coins now have fewer obstacles blocking their growth.
This architectural glass manufacturer, serving major markets across the Americas, reported a recent insider buy in official filings.
Rising oil prices are pressuring the cruise operator.
Alpha Metallurgical Resources, a major U.S. coal supplier, reported a recent insider buy following a year of strong stock performance.
Specializing in advanced semiconductor substrates, this materials supplier reported a notable insider sale amid ongoing sector demand.
Two jury verdicts highlight a new risk facing Meta.